GSK’s 5-in-1 Meningococcal Vaccine Candidate BLA Accepted by FDA: A Potential Game-Changer in IMD Prevention
The FDA has accepted GSK’s BLA for a 5-in-1 meningococcal vaccine candidate, which promises streamlined immunization and a potential reduction in invasive meningococcal disease (IMD).